Hyman Charles D Sells 900 Shares of Amgen Inc. (NASDAQ:AMGN)

Hyman Charles D reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 10.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,002 shares of the medical research company’s stock after selling 900 shares during the quarter. Hyman Charles D’s holdings in Amgen were worth $1,991,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in AMGN. Norges Bank bought a new stake in shares of Amgen in the 4th quarter valued at about $1,302,778,000. Morgan Stanley increased its stake in Amgen by 13.8% during the 4th quarter. Morgan Stanley now owns 9,745,556 shares of the medical research company’s stock worth $2,240,698,000 after purchasing an additional 1,179,665 shares in the last quarter. Boston Partners increased its stake in Amgen by 4,644.8% during the 4th quarter. Boston Partners now owns 972,579 shares of the medical research company’s stock worth $223,616,000 after purchasing an additional 952,081 shares in the last quarter. FIL Ltd increased its stake in Amgen by 199.4% during the 4th quarter. FIL Ltd now owns 853,277 shares of the medical research company’s stock worth $196,185,000 after purchasing an additional 568,324 shares in the last quarter. Finally, Beutel Goodman & Co Ltd. increased its stake in Amgen by 67.0% during the 4th quarter. Beutel Goodman & Co Ltd. now owns 1,028,961 shares of the medical research company’s stock worth $236,578,000 after purchasing an additional 412,976 shares in the last quarter. 75.23% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:AMGN traded down $0.29 during midday trading on Tuesday, reaching $245.09. 103,440 shares of the company were exchanged, compared to its average volume of 2,714,429. The company has a current ratio of 2.28, a quick ratio of 1.88 and a debt-to-equity ratio of 3.12. The business’s fifty day moving average is $248.86 and its two-hundred day moving average is $236.11. Amgen Inc. has a one year low of $210.28 and a one year high of $276.69. The stock has a market cap of $141.12 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76.

Amgen (NASDAQ:AMGN) last announced its earnings results on Monday, April 26th. The medical research company reported $3.70 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $4.05 by ($0.35). Amgen had a net margin of 29.42% and a return on equity of 95.55%. The firm had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $6.30 billion. During the same period in the prior year, the company posted $4.17 EPS. The company’s revenue was down 4.2% compared to the same quarter last year. As a group, sell-side analysts expect that Amgen Inc. will post 16.15 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 8th. Investors of record on Monday, May 17th will be given a $1.76 dividend. This represents a $7.04 annualized dividend and a dividend yield of 2.87%. The ex-dividend date of this dividend is Friday, May 14th. Amgen’s payout ratio is 47.50%.

Several equities research analysts have recently commented on the company. The Goldman Sachs Group reissued a “buy” rating and issued a $290.00 price objective on shares of Amgen in a report on Wednesday, April 28th. Royal Bank of Canada dropped their price target on shares of Amgen from $220.00 to $217.00 and set a “sector perform” rating for the company in a research note on Tuesday. Morgan Stanley dropped their price target on shares of Amgen from $281.00 to $278.00 and set an “overweight” rating for the company in a research note on Monday. Cantor Fitzgerald raised their price target on shares of Amgen from $280.00 to $295.00 and gave the company an “overweight” rating in a research note on Wednesday, February 3rd. Finally, SVB Leerink dropped their price target on shares of Amgen from $267.00 to $230.00 and set a “market perform” rating for the company in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. Amgen has an average rating of “Hold” and a consensus price target of $255.62.

In other news, Director Ronald D. Sugar sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, April 14th. The stock was sold at an average price of $249.98, for a total transaction of $249,980.00. Following the sale, the director now directly owns 16,927 shares in the company, valued at approximately $4,231,411.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jonathan P. Graham sold 11,110 shares of the firm’s stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $236.51, for a total value of $2,627,626.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,360 shares of company stock worth $3,407,034. 0.36% of the stock is owned by insiders.

About Amgen

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.

Read More: What is the Federal Reserve?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.